190 related articles for article (PubMed ID: 37627093)
61. Chromogranin A as a Biochemical Marker for Neuroendocrine Tumors: A Single Center Experience at Royal Hospital, Oman.
Al-Risi ES; Al-Essry FS; Mula-Abed WS
Oman Med J; 2017 Sep; 32(5):365-370. PubMed ID: 29026467
[TBL] [Abstract][Full Text] [Related]
62. Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours.
Lewis AR; Wang X; Magdalani L; D'Arienzo P; Bashir C; Mansoor W; Hubner R; Valle JW; McNamara MG
World J Gastroenterol; 2018 Feb; 24(6):671-679. PubMed ID: 29456406
[TBL] [Abstract][Full Text] [Related]
63. Multidisciplinary team management of carcinoid heart disease.
Steeds R; Sagar V; Shetty S; Oelofse T; Singh H; Ahmad R; Bradley E; Moore R; Vickrage S; Smith S; Yim I; Elhassan YS; Venkataraman H; Ayuk J; Rooney S; Shah T
Endocr Connect; 2019 Dec; 8(12):R184-R199. PubMed ID: 31751305
[TBL] [Abstract][Full Text] [Related]
64. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
Mehnert JM; Bergsland E; O'Neil BH; Santoro A; Schellens JHM; Cohen RB; Doi T; Ott PA; Pishvaian MJ; Puzanov I; Aung KL; Hsu C; Le Tourneau C; Hollebecque A; Élez E; Tamura K; Gould M; Yang P; Stein K; Piha-Paul SA
Cancer; 2020 Jul; 126(13):3021-3030. PubMed ID: 32320048
[TBL] [Abstract][Full Text] [Related]
65. Prospective evaluation and treatment of familial carcinoid small intestine neuroendocrine tumors (SI-NETs).
Hughes MS; Azoury SC; Assadipour Y; Straughan DM; Trivedi AN; Lim RM; Joy G; Voellinger MT; Tang DM; Venkatesan AM; Chen CC; Louie A; Quezado MM; Forbes J; Wank SA
Surgery; 2016 Jan; 159(1):350-6. PubMed ID: 26454678
[TBL] [Abstract][Full Text] [Related]
66. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total
Tirosh A; Papadakis GZ; Millo C; Sadowski SM; Herscovitch P; Pacak K; Marx SJ; Yang L; Nockel P; Shell J; Green P; Keutgen XM; Patel D; Nilubol N; Kebebew E
Eur J Endocrinol; 2017 May; 176(5):575-582. PubMed ID: 28289088
[TBL] [Abstract][Full Text] [Related]
67. Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST.
Srirajaskanthan R; Pavel M; Kulke M; Clement D; Houchard A; Keeber L; Weickert MO
Clin Ther; 2021 Oct; 43(10):1779-1785. PubMed ID: 34598813
[TBL] [Abstract][Full Text] [Related]
68. Effect of hormone secretory syndromes on neuroendocrine tumor prognosis.
Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
Endocr Relat Cancer; 2017 Jul; 24(7):R261-R274. PubMed ID: 28483790
[TBL] [Abstract][Full Text] [Related]
69. The Influence of Preoperative Symptoms on the Death of Patients with Small Intestinal Neuroendocrine Tumors.
Eriksson J; Garmo H; Hellman P; Ihre-Lundgren C
Ann Surg Oncol; 2017 May; 24(5):1214-1220. PubMed ID: 27904972
[TBL] [Abstract][Full Text] [Related]
70. Managing carcinoid heart disease in patients with neuroendocrine tumors.
Koffas A; Toumpanakis C
Ann Endocrinol (Paris); 2021 Jun; 82(3-4):187-192. PubMed ID: 33321109
[TBL] [Abstract][Full Text] [Related]
71. Prognostic Factors for Survival among Patients with Small Bowel Neuroendocrine Tumours Associated with Mesenteric Desmoplasia.
Laskaratos FM; Diamantopoulos L; Walker M; Walton H; Khalifa M; El-Khouly F; Koffas A; Demetriou G; Caplin M; Toumpanakis C; Mandair D
Neuroendocrinology; 2018; 106(4):366-380. PubMed ID: 29320779
[TBL] [Abstract][Full Text] [Related]
72. Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome.
Shi DD; Yuppa DP; Dutton T; Brais LK; Minden SL; Braun IM; Kulke MH; Chan JA; Meyer FL
Cancer; 2017 Jul; 123(14):2735-2742. PubMed ID: 28267211
[TBL] [Abstract][Full Text] [Related]
73. A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival.
Modlin IM; Gustafsson BI; Pavel M; Svejda B; Lawrence B; Kidd M
Neuroendocrinology; 2010; 92(3):143-57. PubMed ID: 20733279
[TBL] [Abstract][Full Text] [Related]
74. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
[TBL] [Abstract][Full Text] [Related]
75. Genetics and epigenetics in small intestinal neuroendocrine tumours.
Stålberg P; Westin G; Thirlwell C
J Intern Med; 2016 Dec; 280(6):584-594. PubMed ID: 27306880
[TBL] [Abstract][Full Text] [Related]
76. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin.
Kema IP; de Vries EG; Schellings AM; Postmus PE; Muskiet FA
Clin Chem; 1992 Apr; 38(4):534-40. PubMed ID: 1373675
[TBL] [Abstract][Full Text] [Related]
77. Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review.
La Salvia A; Portigliatti Pomeri A; Persano I; Trevisi E; Parlagreco E; Colombi N; Brizzi MP; Picci RL; Oliva F
Compr Psychiatry; 2021 Aug; 109():152244. PubMed ID: 34120056
[TBL] [Abstract][Full Text] [Related]
78. Biochemical diagnosis of neuroendocrine GEP tumor.
Oberg K
Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
[TBL] [Abstract][Full Text] [Related]
79. Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours.
van der Horst-Schrivers AN; Post WJ; Kema IP; Links TP; Willemse PH; Wymenga AN; de Vries EG
Eur J Cancer; 2007 Dec; 43(18):2651-7. PubMed ID: 17825550
[TBL] [Abstract][Full Text] [Related]
80. Grade 3 Neuroendocrine Tumor (G3 NET) in a Background of Multiple Serotonin Cell Neoplasms of the Ileum Associated with Carcinoid Syndrome and Aggressive Behavior.
Capuano F; Grami O; Pugliese L; Paulli M; Pietrabissa A; Solcia E; Vanoli A
Endocr Pathol; 2018 Dec; 29(4):369-373. PubMed ID: 30076568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
